WHO WE ARE
Graft Polymer (UK) Plc (LSE: GPL) was established in 2017 by a group of polymer technology experts and venture capitalists. Graft Polymer’s core business comprises polymer modification and the development of drug delivery systems. The Group is a highly innovative business with strong intellectual property holding several patent applications.
Our motto, “COMBINE INCOMPATIBLE”, defines the nature of our business: to create polymer modifiers to combine immiscible and incompatible components of polymer alloys to achieve cost-effective polymers with high mechanical characteristics, chemical resistance, and fire-retardant properties.
Graft Polymer offers bespoke, adapted, and tailored products for customer requests.
Our market-leading expertise and industry knowledge offer the best solution for your application requirements.
Graft Polymer’s innovative nano-methods of manufacturing technologies can offer a tailored solution or multi-composite structure that can deliver performance, functionality, and economic advantages.
In 2020, the Group launched a new division named GraftBio to develop IP for Bio/Pharma applications. This includes Bio Supplements and drug delivery systems to support and provide solutions to the market, which had been heavily impacted by the COVID-19 pandemic.
We welcome any offers from distributors and strategic partners to make new business opportunities. To get in touch, please visit the ‘Contact Us’ page of our site.
WHAT CAN WE OFFER
RESEARCH & DEVELOPMENT
Over 20 years of engineering experience guarantee production of new composite materials with unique features.
PRODUCT CUSTOMIZATION ("TURN-KEY")
We provide full product customization for any demand.
Graft Polymer features a wide range of innovative polymer modifiers and compounds for commercial purposes.
Polymer modification is a 🔑 for creating polymer composite materials.